| Old Articles: <Older 6801-6810 Newer> |
|---|
 |
The Motley Fool
October 20, 2010
Brian Orelli |
What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back.   |
The Motley Fool
October 20, 2010
Brian Orelli |
There Are No Safe Biotech Investments Amylin Pharmaceuticals and its partners, Eli Lilly and Alkermes, announced yesterday evening that the Food and Drug Administration had asked for more data before approving its once-weekly diabetes drug Bydureon. |
The Motley Fool
October 20, 2010
Seth Jayson |
Digging Into the Cash Flow at Biogen Idec Let's compare Biogen Idec's free cash flow to industry peers and competitors to see how they stack up. |
The Motley Fool
October 20, 2010
Seth Jayson |
Where Is Bristol-Myers Squibb's Bottom Line Headed? Here's the current margin snapshot for Bristol-Myers Squibb and some of its sector and industry peers and direct competitors. |
The Motley Fool
October 19, 2010
Brian Orelli |
When the Status Quo Is a Big Win The lack of an FDA rejection will do just fine. Amgen and Johnson & Johnson seemed to get through the FDA advisory panel process without much problem yesterday. |
The Motley Fool
October 19, 2010
Brian Orelli |
Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency. |
The Motley Fool
October 19, 2010
Brian Stoffel |
Would Peter Lynch Like This Micro Cap? Let's see how this tiny stock, Female Health Co., the manufacturer and distributor of the female condom, measures up to Lynch's criteria. |
The Motley Fool
October 19, 2010
Travis Hoium |
Cell Therapeutics Shares Popped: What You Need to Know Cell Therapeutics shares jumped 11% today on news the company received a positive opinion for Pixuvri. |
The Motley Fool
October 18, 2010
Anand Chokkavelu |
There Are Better Opportunities Than Boston Scientific Let's take a look. By the numbers, Abbott, Medtronic, and Johnson & Johnson all look more compelling than Boston Scientific. |
The Motley Fool
October 18, 2010
Brian Orelli |
Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs. |
| <Older 6801-6810 Newer> Return to current articles. |
